|
重组人生长激素治疗青春期前生长激素缺乏症的临床观察 |
| |
覃舒文 史轶蘩 王德芬 高玉琪 谢永明 邓洁英 孙文鑫 高桦 苏文凌
【摘要】 目的 探讨重组人生长激素(rhGH)对青春期前特发性生长激素缺乏症(IGHD)患者的疗效。方法 对3家医院的63例IGHD以rhGH进行治疗，每晚临睡前皮下注射0.1 IU/kg共6个月。结果 63例患儿身高平均增加(7.0±1.6)厘米，年生长速度由治疗前的(2.9±0.9)厘米/年，增加到(14.0±3.2)厘米/年，身高标准差计分(SDS)由治疗前的(-4.8±1.7)变为(-3.9±1.6)；体重也明显增加，但对骨龄无明显促进作用。治疗期间有39.7%的患儿出现亚临床甲状腺功能低减，22.4%的患儿于注射局部曾出现短暂的红肿或痒等，7.9%的患儿出现血清ALT轻度升高，但所有这些现象均未影响患儿体格的线性增长。结论 rhGH是治疗IGHD的一种安全、有效的促生长药物。
【关键词】 特发性生长激素缺乏症 重组人生长激素
A prospective study of therapeutic effect of
recombinant human growth hormone in idiopathic growth hormone deficient children before adolescence
QIN Shuwen,SHI Yifan,WANG Defen,et al.
Department of Endocrinology,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing,100730
【Abstract】 Objective To assess the efficacy of recombinant human growth hormone (rhGH), produced by Shanghai Institute of Cell Biology, in idiopathic growth hormone deficient (IGHD) children before puberty. Methods This noncomparative multicentre prospective study included 63 children (7 girls and 56 boys) with IGHD, who were treated with daily sc injections of rhGH (0.1 IU/kg) before sleep for six months. Results The mean height, mean growth velocity and mean height SDS increased from (119.7±11.8)cm, (2.9±0.9)cm/year and -4.8±1.7 to (126.7±114.4)cm, (14.0±3.2)cm/year and -3.9±1.6, respectively (P＜0.05).At the same time, the mean weight also increased strikingly, but no advanced bone maturation was noted. During the course of rhGH therapy, there were 39.7%, 22.4% and 7.9% patients suffering from subclinical hypothyroidism, local reactions in injection sites and slight increment of the serum ALT levels respectively. All of these phenomena had no effect of their linear body growth. Conclusion rhGH appears an effective and safe drug for promoting growth in IGHD.
【Key word[1] [2] [3] 下一页
上一个医学论文： 生长激素对心功能作用的探讨
下一个医学论文： 中国儿童1型糖尿病发病率的研究
|
|
|
|
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文